New Data Highlights Importance of Umbilical Cord Blood for Transplantation

BERLIN, May 5 -- ViaCell, Inc. (Nasdaq: VIAC) today presented data at the 12th Annual Meeting of the International Society for Cellular Therapy (ISCT) supporting the importance of family banked umbilical cord blood, a non-controversial source of stem cells with proven clinical utility in treating over 40 diseases. The presented data relate to transplantation outcomes and CD34 cell enumeration. These data further support the medical value of cord blood stem cells. ViaCell offers expecting parents the ability to collect and store umbilical cord blood at the birth of their child with ViaCord(R), its product offering for the preservation of cord blood for related use.

ViaCell Reports First Quarter 2006 Financial Results

CAMBRIDGE, Mass., May 2 -- ViaCell, Inc. (Nasdaq: VIAC) today announced its consolidated financial results for the three months ended March 31, 2006.

Total revenues in the first quarter of 2006 were $12.1 million compared to total revenues of $10.1 million for the same period in 2005. Sales of ViaCord(R), ViaCell's product for the preservation of umbilical cord blood, generated revenues of $11.9 million in the first quarter of 2006, a 20 percent increase over the $10.0 million of revenues in the same period in 2005…

ViaCell's 2005 Annual Report

First FDA Clearance of Sterile Field Cord Blood Collection Bag ViaCell and Pall Announce Collaborative Agreement

EAST HILLS, N.Y. and CAMBRIDGE, Mass., April 25 -- ViaCell, Inc. (Nasdaq: VIAC) and Pall Corporation (NYSE: PLL) announced today the first U.S. Food and Drug Administration clearance of a cord blood collection bag suitable for use in a sterile field. Pall and ViaCell collaborated on the development and design of the new collection bag. ViaCell has exclusive rights to the new collection bag for family cord blood banking and expects to introduce it as part of its ViaCord(R) collection kit. The new sterile field bag will give families and their health care providers the ability to more safely and easily collect umbilical cord blood from newborns, even when born by cesarean section.

Umbilical cord blood is a valuable source of stem cells used to treat more than 40 life threatening diseases including a wide range of cancers, immune deficiencies and genetic disorders. Collection of cord blood is a critical first step in the process of preserving a baby's umbilical cord blood to meet these and other future medical needs. It is important that the collection kit simply and aseptically collect as much blood as possible since larger units for cord blood generally produce more viable stem cells.

"I believe the new ViaCord collection bag provides a significant benefit to the obstetrician," said Yoni Branhard, M.D., Vice Chairman of the OB-GYN Department, Lenox Hill Hospital, New York City. "This is an innovative initiative in cord blood banking. The sterile bag gives my colleagues and me the comfort that, no matter how we deliver a child -- vaginally or by cesarean -- we are collecting the cord blood in a high quality manner."

ViaCell Reports Encouraging Preclinical Findings of Unrestricted Somatic Stem Cells from Cord Blood

ATLANTA, March 13 -- ViaCell, Inc. (Nasdaq: VIAC) announced today preclinical findings evaluating Unrestricted Somatic Stem Cells (USSCs), pluripotent stem cells cultivated from human cord blood, in a small animal model of myocardial infarction. In the study USSCs showed a dose-dependent response and result in functional recovery in an animal model of acute myocardial infarction four weeks post transplantation…

"These data are very exciting as we've seen few examples of a dose- dependent effect of stem cells demonstrated in the cardiac field thus far. While further research is needed, we also demonstrated USSCs differentiate into both endothelial and cardiomyocytes," said Dr. Takayuki Asahara of Kobe Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology. "Through our work with ViaCell evaluating their proprietary USSCs, we are encouraged about the potential these cells may have to regenerate damaged heart tissue…"

"We are encouraged with these research findings and intend to advance this program further in preclinical testing to determine optimal dosing, delivery, and targeting of USSCs as a treatment for cardiac disease. With over 800,000 annual cases of patients surviving a myocardial infarction and 5 million people suffering from chronic heart failure and no proven therapy to repair or regenerate the heart, we believe our USSC program is an important initiative," said Stephan Wnendt, Ph.D., Senior Vice President of Research and Development at ViaCell…